Safety in numbers--monitoring risk in approved drugs.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  New England Journal of Medicine

• Publication date

  2005-03-24

• Fields of study

  Law, Medicine

• Identifiers
  DOI 10.1056/NEJMP058029PMID 15788493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.

  2005cited by this paper
• Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

  2004cited by this paper
• Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis

  2004cited by this paper

• Regulatory bodies and health care systems should systematically evaluate the safety and cost-effectiveness of new cardiovascular treatments in health care registries using prospectively designed protocols

  2024cites this paper
• Chemical Regulation

  2021cites this paper
• Pharmacovigilance

  2021cites this paper
• Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH

  2017cites this paper
• The Impact of the Sentinel Initiative and FAERS Surveillance System on Consumer Safety

  2016influential citation
• Skin autoimmune disorders: lipid biopolymers and colloidal delivery systems for topical delivery

  2016cites this paper
• Neuroethical Issues in the Diagnosis and Treatment of Children with Mood and Behavioral Disturbances

  2015cites this paper
• Integration of PKPD relationships into benefit–risk analysis

  2015cites this paper
• Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants

  2015cites this paper
• Evaluating the Impact of Treatment Effectiveness and Side Effects in Prescribing Choices

  2014cites this paper
• One Less Risk, Or One Less Girl? Situating Gardasil and Cervical Cancer Risk in the Context of Risk-Reduction Medicine

  2014cites this paper
• EU marketing authorization review of orphan and non-orphan drugs does not differ.

  2013cites this paper
• Post-Marketing Surveillance of Prescription Drug Safety: Past, Present, and Future

  2013cites this paper
• Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist

  2013cites this paper
• Pharmacovigilance Systems in Developing Countries: An Evaluative Case Study in Burkina Faso

  2013cites this paper
• Adverse drug reactions as the cause of emergency department admission of patients aged 80 years and older.

  2012cites this paper
• Statistical aspects in comparative benefit‐risk assessment: challenges and opportunities for pharmaceutical statisticians

  2012cites this paper
• Improvement of drug safety by the use of lipid-based nanocarriers.

  2012cites this paper
• Troubled Children: Diagnosing, Treating, and Attending to Context

  2011cites this paper
• Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

  2011cites this paper
• The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

  2011cites this paper
• Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness.

  2011cites this paper
• [Proton pump inhibitors and infection risk].

  2011cites this paper
• Phase IV: Postmarketing Trials

  2010cites this paper
• Fixing flaws in Medicare drug coverage that prompt insurers to avoid low-income patients.

  2010cites this paper
• Adverse Drug Reactions: Part II

  2010cites this paper
• Adverse drug reactions: Part I.

  2010cites this paper
• A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.

  2010cites this paper
• Evaluating the evidence base in pharmacovigilance decision making

  2010cites this paper
• Safety-Related Regulatory Actions for Orphan Drugs in the US and EU

  2010cites this paper
• Assessing long-term drug safety: lessons (re) learned from raptiva.

  2010cites this paper
• The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening.

  2009cites this paper
• U.S. Pharmacy Policy: A Public Health Perspective on Safety and Cost

  2009cites this paper
• Reporting adverse drug reactions.

  2009cites this paper
• Pharmaceutical product withdrawal: attributions of blame and its impact on trust.

  2009cites this paper
• Causality assessment in hepatotoxicity by drugs and dietary supplements.

  2008cites this paper
• Outsourcing in the Healthcare Industry: Information Technology, Intellectual Property, and Allied Aspects

  2008cites this paper
• Long-term treatment for severe psoriasis: we're halfway there, with a long way to go.

  2007cites this paper
• Beyond post-marketing research and MedWatch: Long-term studies of drug risks

  2007cites this paper
• [Toxic liver disease due to drugs, herbs and dietary supplements: diagnostic approaches].

  2007cites this paper
• Antidepressants & suicide: putting the risk in perspective.

  2007cites this paper
• Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.

  2007cites this paper
• Antidepressants and Suicide: Putting the Risk in Perspective

  2007cites this paper
• Toxische Leberschäden durch arzneiliche, pflanzliche und nahrungsergänzende Mittel: Diagnostische Möglichkeiten

  2007cites this paper
• Role of active surveillance in improving hospital adverse drug event monitoring

  2006influential citation
• The highest drug-safety spenders among drug firms produce more new and "blockbuster" drugs than their competitors do.

  2006cites this paper
• Reform of drug regulation--beyond an independent drug-safety board.

  2006cites this paper
• How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.

  2006cites this paper
• Muraglitazar and the FDA: what constitutes drug safety?

  2006cites this paper
• Muraglitazar and the FDA: what constitutes drug safety?

  2006cites this paper
• Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.

  2006cites this paper
• Evaluation of drug toxicity in clinical trials

  2006cites this paper
• Spending on postapproval drug safety.

  2006cites this paper
• Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

  2006cites this paper
• Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk

  2006cites this paper
• From bench to bedside

  2005cites this paper
• A Commentary on the American Society for Clinical Pharmacology and Therapeutics Position Statement on Dietary Supplement Safety and Regulation

  2005cites this paper
• Medical paternalism and expensive unsubsidised drugs

  2005cites this paper
• Abstracts of the 7th Annual Congress on Clinical Pharmacology

  2005influential citation
• Quels enseignements méthodologiques tirer de la mise en évidence tardive de la toxicité cardiovasculaire de certains coxibs

  2005cites this paper
• NSAID-Associated Deaths: The Rise and Fall of NSAID-Associated GI Mortality

  2005cites this paper
• Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus: what can this teach us?

  2005cites this paper
• The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis

  2005cites this paper
• Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs.

  2005cites this paper
• Drug-induced liver disease

  1990cites this paper